Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Schuller

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Journal of Molecular Endocrinology|August 1, 1997
IGF, type I IGF receptor and IGF-binding protein mRNA expression in kidney and liver of potassium-depleted and normal rats infused with IGF-IJ W van Neck, A Flyvbjerg, A G Schuller, et al.
The European Journal of Neuroscience|September 10, 2004
Mu-opioid receptor knockout mice show diminished food-anticipatory activityMartien J H Kas, Ruud van den Bos, Annemarie M Baars, et al.
Nature Neuroscience|April 9, 1999
Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1A G Schuller, M A King, J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR InhibitionHannah A Scarborough, Barbara A Helfrich, Matias Casás-Selves, et al.
Endocrinology|December 1, 1999
Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to -6: comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryoM van Kleffens, C A Groffen, N F Dits, et al.
Molecular Cancer Therapeutics|May 24, 2013
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapyAmy D Guertin, Jing Li, Yaping Liu, et al.
Oncotarget|July 30, 2016
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activationRyan E Henry, Evan R Barry, Lillian Castriotta, et al.
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
Molecular Pharmaceutics|December 10, 2021
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy OutcomesChristina Vasalou, Douglas Ferguson, Weimin Li, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Journal of Molecular Endocrinology|August 1, 1997
IGF, type I IGF receptor and IGF-binding protein mRNA expression in kidney and liver of potassium-depleted and normal rats infused with IGF-IJ W van Neck, A Flyvbjerg, A G Schuller, et al.
The European Journal of Neuroscience|September 10, 2004
Mu-opioid receptor knockout mice show diminished food-anticipatory activityMartien J H Kas, Ruud van den Bos, Annemarie M Baars, et al.
Nature Neuroscience|April 9, 1999
Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1A G Schuller, M A King, J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR InhibitionHannah A Scarborough, Barbara A Helfrich, Matias Casás-Selves, et al.
Endocrinology|December 1, 1999
Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to -6: comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryoM van Kleffens, C A Groffen, N F Dits, et al.
Molecular Cancer Therapeutics|May 24, 2013
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapyAmy D Guertin, Jing Li, Yaping Liu, et al.
Oncotarget|July 30, 2016
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activationRyan E Henry, Evan R Barry, Lillian Castriotta, et al.
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
Molecular Pharmaceutics|December 10, 2021
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy OutcomesChristina Vasalou, Douglas Ferguson, Weimin Li, et al.
Pageof 10